Cardiovascular toxicities associated with novel cellular immune therapies
Abstract. Over the past decade, T-cell–directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapies
Related Articles
China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.
Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.
Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response
Key PointsAdding navitoclax to ongoing ruxolitinib demonstrates durable responses and potential disease modification in relapsed/refractory MF.Thrombocytop
Guideline Task Force Nomination Application – American Society for Radiation Oncology (ASTRO)
ASTRO welcomes nominations for participation in upcoming practice guidelines. Please complete this form for consideration.
Novel HER2 TKI Shows Preliminary Activity in Breast Cancer Brain Metastases
Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.
Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel
Panelists discuss how the major unmet needs in treating synovial sarcoma include developing targeted therapies that effectively address the SS18::SSX fusion oncogene, improving early detection…
Addition of an immune checkpoint inhibitor reduces the risk of disease progression for select patients with anal cancer
Click on the article title to read more.
